This video is created for healthcare professionals for the sole purpose of medical education. This video is sponsored by Bayer. The speaker did not receive compensation from Bayer for the development, recording or posting of this video. The views expressed are those of the named speakers.
Prescribing Information for Lynkuet™ (elinzanetant▼) is available here for Canada and here for the EU. Local prescribing conditions may vary. Please refer to prescribing information in your country of practice.▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Details on adverse event reporting are given at the end of this page.
In this short segment filmed at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, Ludwig Kiesel explains the clinical burden of treatment‑induced vasomotor symptoms (VMS), why this issue matters to patients, and the real‑world ways these symptoms affect daily life.
He also summarises findings from a systematic review of more than 200 studies and highlights evidence showing how VMS can influence adherence among women receiving adjuvant endocrine therapy for breast cancer.1
Key points from the interview
- VMS are common in women on adjuvant endocrine therapy and are associated with poorer quality of life, including sleep disturbances, mood changes, and reduced daily functioning.
- Evidence on the economic impact is limited, but real‑world data indicate VMS can lower adherence to endocrine therapy; targeted interventions are needed to relieve these disruptive symptoms and help patients stay on their prescribed treatment.
Elinzanetant is the first dual neurokinin (NK) 1 and 3 receptor antagonist for the non-hormonal treatment of moderate-to-severe VMS associated with menopause or caused by adjuvant endocrine therapy, administered orally once daily. It is thought that by targeting NK1 and NK3 receptors, which can be found centrally in the hypothalamus, and NK1 receptors peripherally in the skin, elinzanetant helps bring balance back to temperature regulation and, additionally, sleep disturbances.2-5
Timestamps:
0:00 – Opening remarks
0:18 – Motivation to conduct this study
0:48 – Key findings
2:08 – Economic and healthcare system burden
2:44 – Implications for clinical practice
3:31 – Explore full poster
Speaker:
Ludwig Kiesel1
1. Professor of Gynecology and Obstetrics, Department of Gynecology and Obstetrics, University Hospital of Münster, Germany
References
- Kiesel L et al. Adjuvant endocrine therapy for hormone receptor-positive breast cancer: a systematic literature review on the burden of induced vasomotor symptoms (iVMS). Poster CN105. ESMO Congress, 17-21 October, 2025.
- European Medicines Agency (EMA). Lynkuet. 2025. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/lynkuet. Last accessed: 5 November 2025.
- Simon JA et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023;30(3):239-46.
- Pinkerton JAV et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024;332(16):1343-54.
- Cardoso F et al. Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer. N Engl J Med. 2025;393(8):753-63.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer AG via online reporting system at https://www.bayer.com/en/health/report-side-effect.
MA-M_ELZ-ALL-0115-1
